PDCD1 and cancer: These cancers reflect a spectrum of response to ICI, with roughly 50% of metastatic melanoma patients responding, nearly 20% of BRCA patients responsive, and the majority of PDAC patients as non-responders to anti-PD-1 immunotherapy [35–37].